This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EDAP Appoints Experienced Lithotripsy Expert To Increase U.S. Sales

LYON, France, Oct. 9, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the appointment of Bill Brown as U.S. based Senior Sales Manager. Mr. Brown joins EDAP's U.S. team to enhance the market penetration of the Company's Sonolith i-move extracorporeal lithotripsy (ESWL) system, expand U.S. lithotripsy sales initiatives, and begin to prepare for potential U.S. Food and Drug Administration (FDA) approval of the Company's Ablatherm-HIFU (High Intensity Focused Ultrasound) device.

Mr. Brown has 20 years of experience in the medical field and more than ten years of success in selling lithotripsy devices in the U.S. market. Mr. Brown is closely connected to the U.S. urology community, and he brings to EDAP his expertise and knowledge of the market as well as his relationships with its key opinion leaders.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "I am very pleased to welcome Bill to our team. His proven track record of expanding sales in the mature lithotripsy marketplace strengthens the positioning of our innovative Sonolith i-move device in the U.S. market. We remain focused on our U.S. oriented strategy and continue to build our team here. Beyond lithotripsy, we are preparing to further address the prostate cancer market should the Ablatherm-HIFU be approved in the U.S."

Mr. Brown added, "I welcome the new challenge in my career. With the Sonolith i-move, EDAP has developed an innovative, modular device with superior ultrasound localization and significant power to treat urinary stones. I am excited to be a part of the EDAP sales team, and look forward to helping EDAP expand their presence in the U.S. market with their existing and new technologies for both lithotripsy and HIFU."

Sonolith i-move is a compact lithotripter with a revolutionary infrared stereo-vision system for real-time, three-dimensional ultrasound localization of urinary stones. With its various modular configurations, Sonolith i-move will replace Sonolith Praktis, an earlier generation lithotripter, and complements the Company's high-end Sonolith I-sys lithotripter, an integration of x-ray and ultrasound localization systems. Sonolith i-move received European (CE) approval in April 2010, Japanese approval in June 2011 and U.S. marketing clearance in August 2011.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs